Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mahdi Fathi & Marzieh Khakifirooz. (2019) Kidney-related operations research: A review. IISE Transactions on Healthcare Systems Engineering 9:3, pages 226-242.
Read now
Read now
Valentina Lorenzoni, Leopoldo Trieste & Giuseppe Turchetti. (2015) The cost–effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet. Expert Review of Pharmacoeconomics & Outcomes Research 15:4, pages 611-624.
Read now
Read now
Articles from other publishers (18)
Zhuolin Zhang, Lele Cai, Hong Wu, Xinglu Xu, Wenqing Fang, Xuan He, Xiao Wang & Xin Li. (2021) Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis. Frontiers in Public Health 9.
Crossref
Crossref
Ewa Marcinkowska. (2020) The Vitamin D System in Humans and Mice: Similar but Not the Same. Reports — Medical Cases, Images, and Videos 3:1, pages 1.
Crossref
Crossref
Daniel M. Sugrue, Thomas Ward, Sukhvir Rai, Phil McEwan & Heleen G. M. van Haalen. (2019) Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. PharmacoEconomics 37:12, pages 1451-1468.
Crossref
Crossref
Chizoba Nwankwo, Shelby L. Corman & Elamin H. Elbasha. (2019) Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. Journal of Infection and Public Health 12:4, pages 502-508.
Crossref
Crossref
Lavinia Negrea. (2019) Active Vitamin D in Chronic Kidney Disease: Getting Right Back Where We Started from?. Kidney Diseases 5:2, pages 59-68.
Crossref
Crossref
Franck Maunoury, Aurore Clément, Chizoba Nwankwo, Laurie Levy-Bachelot, Armand Abergel, Vincent Di Martino, Eric Thervet & Isabelle Durand-Zaleski. (2018) Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. PLOS ONE 13:3, pages e0194329.
Crossref
Crossref
E. Elbasha, W. Greaves, D. Roth & C. Nwankwo. (2017) Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. Journal of Viral Hepatitis 24:4, pages 268-279.
Crossref
Crossref
Luis Manjarres, Pilar Sanchez, María C. Cabezas, Marco Fornasini, Valeria Freire & Adelin Albert. (2016) Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital. BMC Health Services Research 16:1.
Crossref
Crossref
Aoife Corcoran, Sharmin Nadkarni, Kaori Yasuda, Toshiyuki Sakaki, Geoffrey Brown, Andrzej Kutner & Ewa Marcinkowska. (2016) Biological Evaluation of Double Point Modified Analogues of 1,25-Dihydroxyvitamin D2 as Potential Anti-Leukemic Agents. International Journal of Molecular Sciences 17:2, pages 91.
Crossref
Crossref
Joseph F. LevyPatrick D. MeekMarjorie A. Rosenberg. (2014) US-Based Drug Cost Parameter Estimation for Economic Evaluations. Medical Decision Making 35:5, pages 622-632.
Crossref
Crossref
Mark Nuijten, Daniela P. Roggeri, Alessandro Roggeri, Paolo Novelli & Thomas S. Marshall. (2015) Health Economic Evaluation of Paricalcitol® Versus Cincalcet + Calcitriol (Oral) in Italy. Clinical Drug Investigation 35:4, pages 229-238.
Crossref
Crossref
Shunsuke Goto, Hirotaka Komaba, Masafumi Fukagawa & Shinichi Nishi. (2013) Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney International Supplements 3:5, pages 457-461.
Crossref
Crossref
Varun Puri, Tanya L. Pyrdeck, Traves D. Crabtree, Daniel Kreisel, Alexander S. Krupnick, Graham A. Colditz, G. Alexander Patterson & Bryan F. Meyers. (2012) Treatment of Malignant Pleural Effusion: A Cost-Effectiveness Analysis. The Annals of Thoracic Surgery 94:2, pages 374-380.
Crossref
Crossref
Yeohan Song, Julie H.Y. Tai, Sarah M. Bartsch, Richard K. Zimmerman, Robert R. Muder & Bruce Y. Lee. (2012) The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. Vaccine 30:24, pages 3675-3682.
Crossref
Crossref
Varun Puri, Traves D. Crabtree, Steven Kymes, Martin Gregory, Jennifer Bell, Jeffrey D. Bradley, Clifford Robinson, G. Alexander Patterson, Daniel Kreisel, Alexander S. Krupnick & Bryan F. Meyers. (2012) A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: A decision analysis. The Journal of Thoracic and Cardiovascular Surgery 143:2, pages 428-436.
Crossref
Crossref
Mark Nuijten, Dennis L. Andress, Steven E. Marx, Alistair S. Curry & Raimund Sterz. (2010) Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clinical Drug Investigation 30:8, pages 545-557.
Crossref
Crossref
Elżbieta Gocek, Marek Kiełbiński, Hanna Baurska, Olga Haus, Andrzej Kutner & Ewa Marcinkowska. (2010) Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations. Leukemia Research 34:5, pages 649-657.
Crossref
Crossref
Hirotaka Komaba, Kensuke Moriwaki, Isao Kamae & Masafumi Fukagawa. (2009) Towards Cost-effective Strategies for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Japan. Therapeutic Apheresis and Dialysis 13, pages S28-S35.
Crossref
Crossref